A randomized phase III trial of patients with stage II and III colon cancer showed no benefit of adding bevacizumab to standard adjuvant oxaliplatin plus fluorouracil and leucovorin. Despite suggestive evidence of a short-term benefit, these data and other similar findings dictate that adjuvant bevacizumab should not be used in colon cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Triazole RGD antagonist reverts TGFβ1-induced endothelial-to-mesenchymal transition in endothelial precursor cells
Molecular and Cellular Biochemistry Open Access 19 October 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).
Moertel, C. G. et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322, 352–358 (1990).
Andre, T. et al. Oxaliplatin, 5-fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350, 2343–2351 (2004).
Allegra, C. J. et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP Protocol C-08. J. Clin. Oncol. doi:10.1200/JCO.2010.30.0855.
Sargent, D. J. et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J. Clin. Oncol. 23, 8664–8670 (2005).
Investor Update. Roche provides results on Avastin in adjuvant colon cancer [online], (2010).
Van Cutsem, E. et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 27, 3117–3125 (2009).
Alberts, S. R. et al. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage II colon cancer (CC): results from NCCTG intergroup phase III trial N0147 [abstract CRA3507]. J. Clin. Oncol. 28 (Suppl. 18), 959s (2010).
University of Birmingham. FOxTROT [online], (2010).
Quasar Collaborative Group et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370, 2020–2029 (2007).
Acknowledgements
The author would like to thank Dr. Axel Grothey for helpful discussions.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
D. J. Sargent declares that he has previously acted as a consultant for Genentech.
Rights and permissions
About this article
Cite this article
Sargent, D. Failure of bevacizumab in early-stage colon cancer. Nat Rev Clin Oncol 8, 10–11 (2011). https://doi.org/10.1038/nrclinonc.2010.205
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.205
This article is cited by
-
Triazole RGD antagonist reverts TGFβ1-induced endothelial-to-mesenchymal transition in endothelial precursor cells
Molecular and Cellular Biochemistry (2017)
